Buty Cancer Research Results

Buty, Butyrate: Click to Expand ⟱
Source:
Type:

Butyrate (butyric acid) is a four-carbon short-chain fatty acid produced primarily by intestinal microbial fermentation of dietary fibre and resistant starch. It is a major energy source for normal colonocytes and also functions as a signalling metabolite through inhibition of histone deacetylases (HDACs) and activation of receptors including GPR109A/HCAR2 and FFAR2/GPR43. In colorectal cancer cells, butyrate ↑ commonly causes intracellular accumulation, HDAC inhibition, cell-cycle arrest, differentiation, and apoptosis while reducing proliferation and inflammatory signalling. This contrasting effect in normal versus malignant colonocytes is sometimes called the butyrate paradox: normal colonocytes efficiently oxidize butyrate as fuel, whereas glycolytic cancer cells may metabolize less butyrate, permitting greater nuclear accumulation and HDAC inhibition. Butyrate is an individual metabolite and microbial postbiotic, separate from the broader short-chain fatty acid group and from acetate and propionate. Effects outside the colon are dose-, tissue-, microbiome-, and metabolism-dependent, and most direct anticancer evidence remains preclinical. Colorectal cancer reference; Intestinal biology review; HDAC inhibition reference.



Scientific Papers found: Click to Expand⟱
7012- Fuc,    Fucoidan: A promising natural therapeutic agent for protecting human kidney health
- Review, EC, NA
*RenoP↑, *Inflam↓, *antiOx↑, *ROS↓, *BloodF↑, *diuretic↑, *BioAv↓, *BioAv↑, *MAPK↓, *ERK↑, *NLRP3↓, *NRF2↑, *MDA↓, *SOD↑, *GPx↑, *Catalase↑, *lipid-P↓, *DNAdam↓, *Fibrosis↓, *JAK2↓, *STAT3↓, *uricA↓, *COL1↓, *α-SMA↓, *SIRT1↑, *HO-1↑, *GLP-1R↑, *HMGB1↓, *RAGE↓, *NF-kB↓, *TGF-β1↓, *PI3K↓, *Akt↓, *GutMicro↑, *SCFAs↑, *Buty↑, *IBI↑, *TJ↑, *Dose↝,
7669- IP,    Colorectal cancer and inulin supplementation: the good, the bad, and the unhelpful
- Review, CRC, NA
GutMicro↑, Buty↑, eff↓, Inflam↑, eff∅, SCFAs↑,
7659- IP,    Inulin-type fructans and reduction in colon cancer risk: review of experimental and human data
- in-vivo, Colon, NA
GutMicro↑, SCFAs↑, eff↑, Buty↑, Risk↓,
7660- IP,    Overview of experimental data on reduction of colorectal cancer risk by inulin-type fructans
- Review, CRC, NA
SCFAs↑, Buty↑, PA↑, TumCG↓, HDAC↓, Apoptosis↑, TumMeta↓,
7661- IP,    Enhancement of carbohydrate metabolism by probiotic and prebiotic intake promotes short-chain fatty acid production in the gut microbiome: a randomized, double-blind, placebo-controlled crossover trial
- Trial, Nor, NA
*PA↑, *Buty↑, *GutMicro↑, *SCFAs↑,
7664- IP,  GCL2505,    Administration of bifidobacteria and dietary fiber improves cognitive function by increasing short-chain fatty acid-producing bacteria and reducing inflammation
- Trial, AD, NA
*cognitive↑, *SCFAs↑, *GutMicro↑, *Buty↑, *AcOH↑, *neuroP↑,
7666- IP,    Short-chain fatty acid kinetics and concentrations are higher after inulin supplementation in young and older adults: a randomized trial
- Trial, Nor, NA
*Dose↝, *Buty↑, *PA↑, *AcOH↑, *SCFAs↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

Buty↑, 3,   PA↑, 1,   SCFAs↑, 3,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

HDAC↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

TumMeta↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↓, 1,   eff↑, 1,   eff∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 2,  

Functional Outcomes(tgid=23) ⓘ

Risk↓, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AcOH↑, 2,   Buty↑, 4,   diuretic↑, 1,   GLP-1R↑, 1,   PA↑, 2,   SCFAs↑, 4,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,   uricA↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   MAPK↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 1,   PI3K↓, 1,   STAT3↓, 1,  

Migration(tgid=13) ⓘ

COL1↓, 1,   Fibrosis↓, 1,   RAGE↓, 1,   TGF-β1↓, 1,   TJ↑, 1,   α-SMA↓, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

HMGB1↓, 1,   Inflam↓, 1,   JAK2↓, 1,   NF-kB↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   Dose↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

BloodF↑, 1,   GutMicro↑, 3,   RAGE↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 1,   neuroP↑, 1,   RenoP↑, 1,  
Total Targets: 44

Scientific Paper Hit Count for: Buty, Butyrate
6 Inulin Prebiotic
1 Fucoidan
1 Bifidobacterium animalis subsp. lactis GCL2505
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:1564  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page